Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) CEO Sells 6,170 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) CEO Edward M. Md Kaye sold 6,170 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $78,852.60. Following the sale, the chief executive officer now owns 68,671 shares in the company, valued at $877,615.38. This represents a 8.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Stoke Therapeutics Trading Down 3.6 %

STOK traded down $0.50 during trading on Tuesday, reaching $13.26. 1,053,661 shares of the company’s stock were exchanged, compared to its average volume of 749,634. The stock has a market capitalization of $702.38 million, a PE ratio of -6.31 and a beta of 0.95. The firm has a fifty day moving average price of $12.44 and a two-hundred day moving average price of $13.69. Stoke Therapeutics, Inc. has a one year low of $4.09 and a one year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The firm had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Sell-side analysts expect that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. bought a new position in shares of Stoke Therapeutics during the 2nd quarter worth about $19,835,000. SG Americas Securities LLC boosted its holdings in Stoke Therapeutics by 610.3% in the second quarter. SG Americas Securities LLC now owns 68,601 shares of the company’s stock worth $927,000 after acquiring an additional 58,943 shares in the last quarter. RTW Investments LP boosted its holdings in Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after acquiring an additional 427,447 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in Stoke Therapeutics by 54.3% in the third quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock valued at $1,266,000 after acquiring an additional 36,240 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after acquiring an additional 1,123,500 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on STOK. Leerink Partners initiated coverage on Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics presently has a consensus rating of “Buy” and an average target price of $20.83.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.